Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
None
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

The study will provide information on outcomes in people with type 1 Gaucher disease when they are treated with velaglucarase alfa (also called VPRIV), under standard care. Standard care means

vpriv
substrate reduction therapy
velaglucerase alfa
type 1 gaucher disease
replacement therapy
  • 0 views
  • 22 May, 2021
  • 1 location
None
Survey Study for Velaglucerase Alfa (VPRIV) in Japan

The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to

vpriv
velaglucerase alfa
  • 74 views
  • 27 Jan, 2021
  • 31 locations
None
A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies

The main aim of this study is to describe the safety profile of velaglucerase alfa (VPRIV) in participants with Gaucher disease type 1. Participants will be transitioning from other enzyme

vpriv
substrate reduction therapy
velaglucerase alfa
type 1 gaucher disease
replacement therapy
  • 12 views
  • 22 Aug, 2021
  • 1 location
None
Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India

The purpose of this post-marketing survey study is to determine the safety and evaluate effectiveness in participants receiving VPRIV when used in the post-marketing setting and to collect and

vpriv
velaglucerase alfa
  • 0 views
  • 21 Aug, 2021
  • 2 locations
None
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

The main aim of this study is to learn if velaglucerase alfa (VPRIV) improves growth and symptoms in participants under 5 years old with Gaucher disease. Symptoms will be checked with blood

vpriv
velaglucerase alfa
  • 0 views
  • 20 Jul, 2021
  • 1 location